This randomised, placebo-controlled study is designed to explore the effects of EVT 302 both with and without concomitant nicotine replacement therapy (NRT) on craving and withdrawal in smokers after short term deprivation of cigarettes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
90
2 X EVT 302, 5 mg tablets
2 X placebo tablets to match EVT 302 5 mg
NRT patch containing 21 mg of nicotine
PAREXEL International GmbH, Clinical Pharmacology Research Unit
Berlin, Germany
Reduction in Craving and withdrawal
Time frame: Within 12 hours of the last cigarette
CogState Cognitive test Battery
Time frame: 12 hours post last cigarette
Breath carbon monoxide levels
Time frame: 12 hours post last cigarette
Salivary cotinine levels
Time frame: 12 hours post last cigarette
Clinical safety lab tests
Time frame: Up to 7 days post dose
Assessment of adverse events
Time frame: Up to 7 days post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Medically inert plaster cut to match the NRT plaster